Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 12Neoplasms 10Carcinoma, Renal Cell 9Ovarian Neoplasms 7Carcinoma, Transitional Cell 7Neoplasm Metastasis 6Pancreatic Neoplasms 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Recurrence 3Lymphoma 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Melanoma 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Kidney Diseases 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1

Interventions

Gemcitabine 4Cisplatin 4Carboplatin 3pembrolizumab 2erdafitinib 2durvalumab 2vinflunine 1tremelimumab 1enfortumab vedotin 1avelumab 1Sunitinib 1Radiotherapy 1Paclitaxel 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urothelial Cancer × avelumab × Clear all
NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
106 enrolled 36 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡